IVD China last week: Danaher, Mindray, Wondfo, Gongdong Medical, Vazyme

Danaher Western China Innovation Center officially launched

On July 10, 2024, the first phase of Danaher's Western China Innovation Center was officially opened in Chongqing. As another milestone of Danaher's local innovation strategy, Danaher will work with domestic and foreign universities, medical institutions, leading biopharmaceutical companies, industrial parks, and investment institutions to build an industrial ecosystem, create a platform for the development of advanced technologies in the west of China, introduce mature management systems, incubate high-precision technology projects, and serve high-level innovation transformation and industrial development in the Sichuan-Chongqing region. It will introduce mature management system, incubate high-precision technology projects, and serve high-level innovation transformation and industrial development in Sichuan and Chongqing regions.

Nanjing Municipal Government signs a strategic cooperation agreement with Mindray

Mindray, which is mainly engaged in medical device R&D, manufacturing, marketing and service, is a global leading medical device and solution provider, and has long established a good cooperative relationship with Nanjing.

According to the agreement, the two sides will carry out all-round, multi-level and wide-field in-depth cooperation in accordance with the principle of "complementary advantages, mutual support, long-term cooperation and common development", focusing on the key directions of upgrading the development capacity of Nanjing base, promoting the transformation and application of scientific research results, and helping to improve the quality and efficiency of the medical field to accelerate the cultivation and development of new productivity and create a new situation of win-win development. 

Wondfo Biotech officially becomes a member of IFCC

In July 2024, Wondfo Biotech officially became a member of IFCC, which will deepen the communication and cooperation between Wondfo Biotech and its international counterparts, obtain the latest industry technology information in a timely manner, and enhance the laboratory's ability of traceability. Wondfo Biotech will also actively participate in the development and promotion of clinical chemistry and laboratory medicine standards, playing a greater role in promoting standardized traceability of laboratory medicine measurements and promoting mutual recognition of results worldwide.

Gongdong Medical’s net profit expected to be $99 million in the first half of 2024

Zhejiang Gongdong Medical Technology Co.,Ltd. (605369) released its 2024 half-yearly performance forecast, showing that during the reporting period, it is expected to realize a net profit attributable to shareholders of the listed company of about 99 million yuan, an increase of about 62.41% year-on-year. Net profit after non-recurring gains and losses will be about 97.3095 million yuan, an increase of about 80.73% year-on-year.

Vazyme: H1 2024 revenue forecast to increase 12.08% to 15.58%

Vazyme released its 2024 Half-Yearly Results Preview, showing that during the reporting period, the company is expected to realize an operating income of 640,000.00 million yuan to 660,000.00 million yuan, which will increase by 68.9631 million yuan to 88.9631 million yuan, or 12.08% to 15.58% year-on-year, compared with the same period of the previous year. It is expected to realize attributable net profit of 15 million yuan to 17 million yuan, compared with the same period of the previous year, will realize a turnaround.